Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors
- PMID:24169554
- DOI: 10.1210/en.2013-1658
Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors
Abstract
Amylin is a neuroendocrine hormone involved in glucose regulation. An amylin analog, pramlintide, is used to treat insulin-requiring diabetes. Its anorexigenic actions give it potential as an obesity treatment. There are 3 amylin receptors (AMY1, AMY2, AMY3), comprising the calcitonin receptor and receptor activity-modifying proteins 1, 2, and 3, respectively. The pharmacology of pramlintide at each subtype has not been determined whereas the unrelated peptide β-amyloid 1-42 (Aβ1-42) has recently been proposed to be a specific agonist of the AMY3 receptor. We investigated the actions of Aβ1-42 and pramlintide, compared with human and rat amylin at the calcitonin receptor, AMY1, AMY2, and AMY3 receptors, measuring the cAMP response in human embryonic kidney 293S and Cos 7 cells. Pramlintide activated all receptors with a slight preference for AMY1. No cAMP response was detected with Aβ1-42 at any receptor, suggesting that it may not be a genuine agonist of AMY receptors.
Similar articles
- Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes.Bailey RJ, Walker CS, Ferner AH, Loomes KM, Prijic G, Halim A, Whiting L, Phillips AR, Hay DL.Bailey RJ, et al.Br J Pharmacol. 2012 May;166(1):151-67. doi: 10.1111/j.1476-5381.2011.01717.x.Br J Pharmacol. 2012.PMID:22014233Free PMC article.
- Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors.Morfis M, Tilakaratne N, Furness SG, Christopoulos G, Werry TD, Christopoulos A, Sexton PM.Morfis M, et al.Endocrinology. 2008 Nov;149(11):5423-31. doi: 10.1210/en.2007-1735. Epub 2008 Jul 3.Endocrinology. 2008.PMID:18599553
- The effects of C-terminal truncation of receptor activity modifying proteins on the induction of amylin receptor phenotype from human CTb receptors.Udawela M, Christopoulos G, Morfis M, Tilakaratne N, Christopoulos A, Sexton PM.Udawela M, et al.Regul Pept. 2008 Jan 10;145(1-3):65-71. doi: 10.1016/j.regpep.2007.08.003. Epub 2007 Aug 16.Regul Pept. 2008.PMID:17884192
- Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development.Bower RL, Hay DL.Bower RL, et al.Br J Pharmacol. 2016 Jun;173(12):1883-98. doi: 10.1111/bph.13496. Epub 2016 May 18.Br J Pharmacol. 2016.PMID:27061187Free PMC article.Review.
- Amylin.Hay DL.Hay DL.Headache. 2017 May;57 Suppl 2:89-96. doi: 10.1111/head.13077.Headache. 2017.PMID:28485843Review.
Cited by
- A second trigeminal CGRP receptor: function and expression of the AMY1 receptor.Walker CS, Eftekhari S, Bower RL, Wilderman A, Insel PA, Edvinsson L, Waldvogel HJ, Jamaluddin MA, Russo AF, Hay DL.Walker CS, et al.Ann Clin Transl Neurol. 2015 Jun;2(6):595-608. doi: 10.1002/acn3.197. Epub 2015 Apr 1.Ann Clin Transl Neurol. 2015.PMID:26125036Free PMC article.
- Receptor-mediated toxicity of human amylin fragment aggregated by short- and long-term incubations with copper ions.Caruso G, Distefano DA, Parlascino P, Fresta CG, Lazzarino G, Lunte SM, Nicoletti VG.Caruso G, et al.Mol Cell Biochem. 2017 Jan;425(1-2):85-93. doi: 10.1007/s11010-016-2864-1. Epub 2016 Nov 1.Mol Cell Biochem. 2017.PMID:27804051
- Neuroprotective Effects of Amylin Analogues on Alzheimer's Disease Pathogenesis and Cognition.Grizzanti J, Corrigan R, Casadesus G.Grizzanti J, et al.J Alzheimers Dis. 2018;66(1):11-23. doi: 10.3233/JAD-180433.J Alzheimers Dis. 2018.PMID:30282360Free PMC article.Review.
- Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy.Al-Keilani MS, Alsmadi DH, Darweesh RS, Alzoubi KH.Al-Keilani MS, et al.Clin Pharmacol. 2018 Mar 5;10:23-29. doi: 10.2147/CPAA.S153780. eCollection 2018.Clin Pharmacol. 2018.PMID:29551915Free PMC article.
- The Importance of Understanding Amylin Signaling Mechanisms for Therapeutic Development in the Treatment of Alzheimer's Disease.Servizi S, Corrigan RR, Casadesus G.Servizi S, et al.Curr Pharm Des. 2020;26(12):1345-1355. doi: 10.2174/1381612826666200318151146.Curr Pharm Des. 2020.PMID:32188374Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous